Larazotide

• Description :

  Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2].

• UNSPSC :

  12352209

• Target :

  Gap Junction Protein

• Type :

  Peptides

• Related Pathways :

  Cytoskeleton

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/larazotide.html

• Purity :

  99.26

• Solubility :

  H2O : 2.5 mg/mL (ultrasonic)

• Smiles :

  NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C32H55N9O10

• Molecular Weight :

  725.83

• References & Citations :

  [1]Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22 (17) :9427.|[2]Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35 (1) :86-94.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 3

• Citation 01 :

  JID Innov. 2025 Apr 3;5 (4) :100369.|EBioMedicine. 2021 Nov:73:103641.|J Dent Res. 2023 Jan;102 (1) :82-92.|Nat Commun. 2020 Jun 19;11 (1) :3151.

• CAS Number :

  [258818-34-7]